Antidepressant use in pregnant and postpartum women

Annual Review of Clinical Psychology

Volumn 10, Issue , 2014, Pages 369-392

  Yonkers, Kimberly A ^a   Blackwell, Katherine A ^a   Glover, Janis ^a   Forray, Ariadna ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Antidepressants; Pregnancy; Serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERATOGENIC AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR DISORDER; BLOOD PLACENTA BARRIER; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FETUS DEATH; FETUS GROWTH; GESTATIONAL AGE; HEART DISEASE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR DEPRESSION; NEONATAL BEHAVIORAL SYNDROME; NERVOUS SYSTEM DEVELOPMENT; NEWBORN DEATH; NEWBORN MORTALITY; NEWBORN PERIOD; PERSISTENT PULMONARY HYPERTENSION; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PUERPERIUM; REVIEW; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY;

ANTIDEPRESSIVE AGENTS; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; PAROXETINE; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84897377913     PISSN: 15485943     EISSN: 15485951     Source Type: Book Series    
DOI: 10.1146/annurev-clinpsy-032813-153626     Document Type: Review

References (119)

1. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, et al. 2010. Maternal use of bupropion and risk for congenital heart defects. Am. J. Obstet. Gynecol. 203:52.e1-6
2. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, Natl. Birth Defects Prev. Study. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med. 356:2684-92
3. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, et al. 2009. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 18:246-52
4. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, et al. 2008. Use of antidepressant medications during pregnancy: A multisite study. Am. J. Obstet. Gynecol. 198:194.e1-5
5. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res. Part B Dev. Reprod. Toxicol. 80:18-27
6. Boucher N, Bairam A, Beaulac-Baillargeon L. 2008. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J. Clin. Psychopharmacol. 28:334-39
7. Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am. J. Obstet. Gynecol. 201:579.e1-8
8. Casper R. 2010. Length of prenatal exposure to selective serotonin reuptake inhibitors (SSRI): Effects on neonatal adaptation and psychomotor development. Neuropsychopharmacology 35:S386
9. Casper RC, Fleisher BE, Lee-Ancajas J, Gilles A, Gaylor E, et al. 2003. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142:402-8
10. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. 2011. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: Effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl.) 217:211-19
11. Chambers CD, Hernandez-Diaz S, Van Marter J, Werler MM, Louik C, et al. 2006. Selective serotoninreuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354:579-87
12. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. 1996. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 335:1010-15
13. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, et al. 2005. Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am. J. Obstet. Gynecol. 192:932-36
14. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, et al. 2006. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. J. Am. Med. Assoc. 295:499-507
15. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. 2000. Birth outcomes following prenatal exposure to fluoxetine. Biol. Psychiatry 48:996-1000
16. Cole JA, Ephross SA, Cosmatos IS, Walker AM. 2007a. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol. Drug Saf. 16:1075-85
17. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. 2007b. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol. Drug Saf. 16:474-84
18. Colvin L, Slack-Smith L, Stanley FJ, Bower C. 2011. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. [Erratum appears in Birth Defects Res. A. Clin. Mol. Teratol. 2011 Apr;91(4):268.] Birth Defects Res. 91:142-52
19. Colvin L, Slack-Smith L, Stanley FJ, Bower C. 2012. Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: A population-based study in Western Australia. CNS Drugs 26:e1-14
20. Costei A, Kozer E, Ho T, Ito S, Koren G. 2002. Perinatal outcome following third trimester exposure to paroxetine. Arch. Pediatr. Adolesc. Med. 156:1129-32
21. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. 2011. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 68:1104-12
22. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. 2010a. Abortion. See Cunningham et al. 2010c, pp. 215-37
23. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. 2010b. Teratology andmedications that affect the fetus. See Cunningham et al. 2010c, pp. 312-33
24. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY, e ds. 2010c. Williams Obstetrics. New York: McGraw Hill
25. Dahl M, Olhager E, Ahlner J. 1997. Paroxetine withdrawal syndrome in a neonate. Br. J. Psychiatry 171:391-92
26. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, et al. 2007. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol. Drug Saf. 16:1086-94
27. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, et al. 2008. Paroxetine and fluoxetine in pregnancy: A prospective, multicentre, controlled, observational study. Br. J. Clin. Pharmacol. 66:695-705
28. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, et al. 2006. Exposure to mirtazapine during pregnancy: A prospecti ve, comparative study of birth outcomes. J. Clin. Psychiatry 67:1280-84
29. Einarson A. 2001. Pregnancy outcome following gestational exposure to venlafaxine: Amulticenter prospective controlled study. Am. J. Psychiatry 158:1728-30
30. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, et al. 2003. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can. J. Psychiatry 48:106-10
31. Einarson A, Choi J, Einarson TR, Koren G. 2009. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: Results from a large prospective database. J. Obstet. Gynaecol. Can. 31:452-56
32. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, et al. 2001. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am. J. Psychiatry 158:1728-30
33. El Marroun H, Jaddoe VWV, Hudziak JJ, Roza SJ, Steegers EAP, et al. 2012. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch. Gen. Psychiatry 69:706-14
34. Ferreira E, Carceller AM, Agogue C, Martin BZ, St-Andre M, et al. 2007. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 119:52-59
35. Gavin N, Gaynes B, Lohr K, Meltzer-Brody S, Gartlehner G, Swinson T. 2005. Perinatal depression: A systematic review of prevalence and incidence. Obstet. Gynecol. 106:1071-83
36. Gentile S. 2010. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr. Bull. 36:518-44
37. Graves ED 3rd, Redmond CR, Arensman RM. 1988. Persistent pulmonary hypertension in the neonate. Chest 93:638-41
38. Greene MF. 2007. Teratogenicity of SSRIs-serious concern or much ado about little? N. Engl. J. Med. 356:2732-33
39. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, et al. 2013. Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and metaanalysis of the best evidence. J. Clin. Psychiatry 74:e293-308
40. Grzeskowiak LE, Gilbert AL, Morrison JL. 2012. Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 32:615-21
41. Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S. 2005. Neonatal symptoms following maternal paroxetine treatment: Serotonin toxicity or paroxetine discontinuation syndrome? J. Psychopharmacol. 19:554-57
42. Hayes RM, Wu P, Shelton RC, Cooper WO, Dupont WD, et al. 2012. Maternal antidepressant use and adverse outcomes: A cohort study of 228,876 pregnancies. Am. J. Obstet. Gynecol. 207:49.e1-9
43. Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. 2005. Antidepressant use during pregnancy and the rates of spontaneous abortions: A meta-Analysis. Ann. Pharmacother. 39:803-9
44. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. 2003. Placental passage of antidepressant medications. Am. J. Psychiatry 160:993-96
45. Herńandez-D́iaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. 2007. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120:e272-82
46. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, et al. 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. BMJ Open 2:e001148
47. Kälĺen B. 2004. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 158:312-16
48. Kälĺen B, Olausson PO. 2008. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 17:801-6
49. Kälĺen BAJ, Otterblad Olausson P. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res. 79:301-8
50. Kessler R, McGonagle K, Zhao S, Nelson C, Hughes M, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51:8-19
51. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, et al. 2012. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. BMJ 344:d8012
52. Klieger-Grossmann C, Weitzner B, Einarson T, Koren G, Einarson A. 2010. The safety of escitalopram in pregnancy: A prospective cohort study. J. Popul. Ther. Clin. Pharmacol. 17(1):e230
53. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. 2010. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis. Clin. Epidemiol. 2:29-36
54. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, et al. 1998. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. J. Am. Med. Assoc. 279(8):609-10
55. Laine K, Heikkinen T, Ekblad U, Kero P. 2003. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60:720-26
56. Lauder JM. 1993. Neurotransmitters as growth regulatory signals: Role of receptors and second messengers. Trends Neurosci. 16:233-40
57. Lawn JE, Blencowe H, Pattinson R, Cousens S, Kumar R, et al 2011. Stillbirths: Where? When?Why? How to make the data count? Lancet 377:1448-63
58. Lennestal R, Kälĺen B. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J. Clin. Psychopharmacol. 27:607-13
59. Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, et al. 2006. Antidepressants in amniotic fluid: Another route of fetal exposure. Am. J. Psychiatry 163:145-47
60. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. 2007. First-Trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N. Engl. J. Med. 356:2675-83
61. Lund N, Pedersen LH, Henriksen TB. 2009. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch. Pediatr. Adolesc. Med. 163:949-54
62. Malm H, Artama M, Gissler M, Ritvanen A. 2011. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstetr. Gynecol. 118:111-20
63. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. 2007. Neonatal outcome following pregnancy exposure to antidepressants: A prospective controlled cohort study. BJOG 115:283-89
64. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, et al. 2006. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am. J. Psychiatry 163:1026-32
65. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Herńandez-D́iaz S. 2011. Medication use during pregnan cy, with particular focus on prescription drugs: 1976-2008. Am. J. Obstet. Gynecol. 205:51.e1-8
66. Moses-Kolko E, Bogen D, Perel J, Bregar A, Uhl K, et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. J. Am. Med. Assoc. 293:2372-83
67. Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. 2006. New parents andmental disorders: A population-based register study. JAMA 296:2582-89
68. Nakhai-Pour HR, Broy P, Berard A. 2010. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can. Med. Assoc. J. 182:1031-37
69. Nikfar S, Abdollahi M, Hendoiee N, Rahimi R. 2012a. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: A meta-Analysis. Value Health 15(7):A638
70. Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. 2012b. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-Analysis. DARU J. Pharm. Sci. 20:75
71. Nordeng H, Spigset O. 2005. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy. Drug Saf. 28:565-81
72. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M. 2012. Pregnancy outcome after exposure to antidepressants and the role ofmaternal depression: Results from theNorwegian Mother and Child Cohort Study. J. Clin. Psychopharmacol. 32:186-94
73. Nulman I, Koren G, Rovet J, Barrera M, Pulver A, et al. 2012. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am. J. Psychiatry 169:1165-74
74. Nulman I, Rovet J, Stewart D, Wolpin J, Pace-Asciak P, et al. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective, controlled study. Am. J. Psychiatry 159:1889-95
75. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336:258-62
76. Oberlander TF, Misri S, Fitzgerald CE, Kostsaras X, Rurak D, Riggs W. 2004. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J. Clin. Psychiatry 65:230-37
77. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, et al. 2007. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med. 161:22-29
78. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. 2006. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 63:898-906
79. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res. Part B Dev. Reprod. Toxicol. 83:68-76
80. Occhiogrosso M, Omran SS, Altemus M. 2012. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: Lessons from clinical and translational studies. Am. J. Psychiatry 169:134-40
81. Pacifici GM, Nottoli R. 1995. Placental transfer of drugs administered to the mother. Clin. Pharmacokinet. 28:235-69
82. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, et al. 1993. Pregnancy outcome following first-Trimester exposure to fluoxetine (Prozac). J. Am. Med. Assoc. 269(17):2246-48
83. Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF, et al. 2007. Birth outcomes following prenatal exposure to antidepressants. J. Clin. Psychiatry 68:1284-89
84. Pedersen LH, Henriksen TB, Olsen J. 2010. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 125:e600-8
85. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. 2009. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ 339:b3569
86. Polen KND, Rasmussen SA, Riehle-Colarusso T, Reefhuis J. 2013. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. Birth Defects Res. A Clin. Mol. Teratol. 97:28-35
87. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. 2013. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: Population based case-control study. BMJ 97:28-35
88. Ramos E, St-Andre M, Berard A. 2010. Association between antidepressant use during pregnancy and infants born small for gestational age. Can. J. Psychiatry Rev. Can. Psychiatr. 55:643-52
89. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. 2008. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br. J. Psychiatry 192:344-50
90. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, et al. 2009. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42:95-100
91. Reis M, Kälĺen B. 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol. Med. 40:1723-33
92. Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hernandez S, et al. 2011. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: The relevance of dose. J. Affect. Disord. 135:208-15
93. Ross L, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, et al. 2013. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: A systematic review and meta-Analysis. JAMA Psychiatry 70:436-43
94. Sanz E, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. 2005. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet 365:482-87
95. Saunders NR, Ek CJ, Habgood MD, Dziegielewska KM 2008. Barriers in the brain: A renaissance? Trends Neurosci. 31:279-86
96. Simon GE, Cunningham ML, Davis RL. 2002. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry 159:2055-61
97. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. 2005. Citalopram use in pregnancy: Prospective comparative evaluation of pregnancy and fetal outcome. Am. J. Obstet. Gynecol. 193:2004-9
98. Smith MV, Sung A, Shah B, Mayes L, Klein DS, Yonkers KA. 2013. Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors. Early Hum. Dev. 89:81-86
99. Spencer M. 1993. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 92:721-22
100. Spong CY, Reddy UM, Willinger M. 2011. Addressing the complexity of disparities in stillbirths. Lancet 377:1635-36
101. Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, et al. 2013. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 309:48-54
102. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. 2007. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am. J. Psychiatry 164:1206-13
103. Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL. 2011. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J. Clin. Psychiatry 72:1002-7
104. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S. 2009. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J. Clin. Psychopharmacol. 29:555-60
105. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, et al. 2008. Psychiatric disorders in pregnant and postpartum women in the United States. Arch. Gen. Psychiatry 65:805-15
106. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, et al. 2000. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: Practice variation and outcomes. Pediatrics 105:14-20
107. Warburton W, Hertzman C, Oberlande TF. 2010. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr. Scand. 121:471-79
108. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, et al. 2006. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am. J. Obstet. Gynecol. 194:961-66
109. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. 2009. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin. Proc. 84:23-27
110. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. 2011. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am. J. Perinatol. 28:19-24
111. Wisner KL. 2011. Impact of SSRI antidepressants and major depression on pregnancy and infant outcomes. Arch. Women's Ment. Health 14:S113
112. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, et al. 2009. Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am. J. Psychiatry 166:557-66
113. World Health Organ. 1992. International Statistical Classification of Diseases and Related Health Problems. Geneva:WHO. 10th rev
114. Wurst KE, Poole C, Ephross SA, Olshan AF. 2010. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: Ameta-Analysis of epidemiological studies. BirthDefects Res. 88:159-70
115. Yonkers K, Wisner K, Stewart D, Oberlander T, Dell D, et al. 2009. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen. Hosp. Psychiatry 31:403-13
116. Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K, et al 2011. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 22:848-54
117. Yonkers KA, Norwitz ER, Smith MV, Lockwood CJ, Gotman N, et al. 2012. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 23:677-85
118. Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, et al. 2004. Management of bipolar disorder during pregnancy and the postpartum period. Am. J. Psychiatry 161:608-20
119. Zeskind P, Stephens L. 2004. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113:368-75.